The FIRSTx Trial for FSGS Patients
FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
FIRSTx is a Phase 2 study testing the safety and effectiveness of an investigational drug called CXA-10 designed to treat FSGS without steroids.
Trial for people with
Primary Focal Segmental Glomerulosclerosis (FSGS)
This study will see if CXA-10 can reduce proteinuria while maintaining stable kidney function in people with FSGS.
What is involved for the Patient?
Throughout the course of the study, researchers will measure how different doses of CXA-10 impact proteinuria and carefully evaluate the kidney related and other effects of CXA-10. CXA-10 will be provided to study participants in the form of a pill taken once a day in the morning with food.
About the drug or intervention
CXA-10 appears to work by reducing inflammation in the glomeruli and helping to prevent scarring. CXA-10 has been evaluated in healthy volunteers.
- Study CoordinatorNoel Howard
- Study Coordinator EmailFIRSTx_Trial@med.umich.edu
- Study Coordinator Phone806-414-9591
- Site NameTexas Tech University Health Sciences Center
- Address1300 South Coulter Street
- SponsorComplexa, Inc.
- Study DrugCXA-10
- Estimated enrollment30
- Estimated end dateJuly, 2019